Explore our validated research and development pipelines engineered to establish quantifiable botanical identity, evaluate harvesting chemotypes, and satisfy international regulatory standards for pharmaceuticals and nutraceuticals.
Precision HPLC, GC, and HPTLC fingerprint development to quantify single and multi-component active botanical markers.
Comprehensive chemotypic assessment across geographical terroirs and seasonal harvest windows to lock optimal raw potency.
Isolation and characterization of alkaloids, saponins, and flavonoids aligned with phenotypic target assays and therapeutic mechanisms.
Targeted cellular-level efficacy assays, enzyme kinetic testing, and cytotoxicity mapping for rapid go/no-go early decisions.
GCP-compliant human clinical trial designs supporting dietary supplement claims substantiation and regulatory botanical drug submissions.
Animal modeling across metabolic, anti-inflammatory, and neuroprotective pathways to confirm physiological bioavailability and safety.
Evidence-based herbal prescription modernizing, compatibility optimization, and microencapsulation for superior stability.
Exhaustive safety dossiers including GLP-aligned Ames testing, micronucleus assays, and acute/sub-chronic oral toxicity.
MedGence (Yineng Pharma), headquartered in Changsha, Hunan, operates as a comprehensive contract research, development, and manufacturing organization. Over 14 years, our team has dismantled the traditional subjectivity of herbal formulations through high-precision analytical chemistry, reproducible process engineering, and rigorous clinical validation.
The international botanical drug and high-potency nutraceutical market is transitioning from commodity-grade powdered extracts to quantified, chemically uniform, and molecularly decoded fractions. Global regulatory bodies require comprehensive impurity profiling, heavy metal elimination, and persistent active batch fidelity.
The global botanical drug and standardized phyto-extract market is projected to eclipse $14.2 Billion by 2032, driven by consumer demand for non-synthetic therapeutics and regulatory pathways such as the FDA Botanical Drug Development Guidance and EMA HMPC herbal monographs.
Regulatory authorities in North America, Europe, and Asia demand multi-constituent fingerprinting beyond generic ratio extracts (e.g., 10:1). Requirements mandate validated HPLC-DAD-MS/MS assays, quantification of toxic pyrrolizidine alkaloids, pesticide residue clearance, and strict heavy metal thresholds.
Sponsors can no longer manage fragmented vendors where research labs, animal testing facilities, and extraction plants operate in silos. Turnkey CRO/CDMO integration ensures direct tech transfer of pilot parameters to commercial stainless-steel extraction trains without loss of compound yield.
Phytochemical development faces complex biological variability. Our proprietary CRO/CDMO framework neutralizes wild variation, poor aqueous solubility, and regulatory non-compliance through systematic analytical methodology.
| Scientific Bottleneck | Commercial Industry Impact | MedGence (Yineng) Proprietary Solution | Verified Project Deliverable |
|---|---|---|---|
| Chemotypic Drift & Seasonal Variation | Inconsistent active concentration between raw material batches, causing batch failure and dosage instability. | Multi-regional geographic mapping coupled with secondary metabolite chromatography profiles across quarterly harvest windows. | Geo-seasonal potency audit matrix defining optimal harvest zones, plant anatomical parts, and timing. |
| Polyphenol & Terpenoid Insolubility | Poor human bio-absorption, requiring excessive oral dosage forms and causing low in vivo efficacy. | Advanced galenic formulation: self-emulsifying drug delivery systems (SEDDS), phytosome complexes, and spray-dried micellar matrices. | Formulation dossiers demonstrating a 3x to 8x increase in relative bioavailability (Cmax / AUC). |
| Scale-Up Degradation of Thermolabile Actives | Pilot assays fail to replicate in 5-ton industrial vacuum concentrators due to thermal degradation and shear stress. | Subcritical low-temperature extraction, countercurrent chromatography, and ceramic membrane physical nanofiltration. | Validated Critical Process Parameters (CPPs) ensuring ≥92% active retention during scale-up. |
| Regulatory Traceability & Safety Proofs | NDIs (New Dietary Ingredients) and botanical drug filings rejected for lacking genotoxicity and GLP-tier dossiers. | Integrated toxicological screening: Ames tests, in vitro micronucleus assays, 90-day sub-chronic rodent studies. | Full CTD-ready Safety & Toxicology Assessment Modules compliant with FDA and EMA guidelines. |
A fully integrated infrastructure linking exploratory chemical screening to cGMP commercial dosage manufacturing, eliminating intermediate margin loss and data disconnects.
Target identification across alkaloids, polyphenols, polysaccharides, and glycosides using bio-affinity ultrafiltration and LC-MS metabolomics.
Quantification of secondary metabolite concentrations across 30+ regional biomes, harvest seasons, and plant morphological segments.
Method validation (ICH Q2(R1)) covering specificity, precision, linearity, and robust HPLC-DAD, GC-FID/MS, and HPTLC fingerprint profiles.
Pre-treatment, macroporous resin dynamic adsorption, crystallization, and flash spray drying protocols designed for high yield and solvent recovery.
Resolving physical and chemical botanical hurdles: organoleptic bitterness masking, moisture sorption reduction, and active content degradation prevention.
Standardized safety screening including LD50 acute lethality, repeated-dose 28/90-day sub-chronic systemic toxicity, and chromosomal aberration assays.
Receptor binding, anti-oxidative ROS clearing, anti-glycation (AGEs) screening, and cytokine suppression (TNF-α, IL-6) in mammalian cell cultures.
Targeted animal disease models covering metabolic syndrome, hepatoprotective endpoints, lipid regulation, and pharmacokinetic (PK/PD) studies.
GCP-monitored Phase I safety, Phase II/III randomized placebo-controlled trials, and post-market surveillance for medical and health registrations.
Reverse-engineering ancient classical medical treatises through modern pharmacology, verifying synergistic multi-herb interactions.
Production of concentrated purified syrups, crystalline extracts, botanical isolates, standardized pastes, and supercritical steam-distilled volatile oils.
Finished delivery across oral liquids, hard-gel capsules, softgels, micro-tablets, enteric effervescents, and vacuum-granulated soluble powders.
Translating complex chemical fractions into tailored commercial matrices meeting market-specific regulatory codes across major consumer markets.
Target Channels: High-growth dietary supplements across North America, Europe, and the Asia-Pacific.
Engineering Scope: Bio-standardized active markers (e.g., total ginsenosides ≥80%, chlorogenic acid ≥50%), moisture-resistant micro-granules for direct compression, microencapsulation for non-acidic gut delivery, and validated human clinical substantiation dossiers supporting label health claims.
Target Channels: Pharmaceutical enterprises developing regulated botanical drug substances under FDA Botanical Drug Guidance or NMPA Class 1/2 innovations.
Engineering Scope: Single compound isolation (purity ≥98.5%), spectroscopic structure elucidation (1H-NMR, 13C-NMR, HR-MS), full impurity mapping, validation of multi-constituent batch constancy, and GLP-standard preclinical dossiers.
Target Channels: High-performance clinical skincare, anti-aging cosmeceuticals, and dermatological barrier preparations.
Engineering Scope: High-clarity water-soluble polyphenols, decolorized and deodorized plant flavonoids, exosome-like plant nanovesicles, and verified transdermal delivery models via Franz cell diffusion testing.
Integrating artificial intelligence into natural molecule mining reduces trial-and-error cycles. MedGence's technological roadmap deploys machine learning models to accelerate lead discovery and bioprocess optimization.
Utilizing deep learning models trained on millions of botanical structures to run virtual high-throughput affinity screening against human target receptors (GPCRs, protein kinases, viral proteases), reducing discovery timelines from years to weeks.
Transitioning industrial manufacturing toward subcritical liquid water extraction and automated continuous Supercritical CO2 (scCO2) separation systems. This eliminates petrochemical solvent residues and maintains zero carbon footprint targets.
Deploying online Process Analytical Technology (PAT) incorporating in-line Near-Infrared (NIR) spectroscopy and UV-Vis flow sensors inside industrial extraction tanks, enabling real-time autonomous active feedback control during commercial scale operations.
Every client engagement follows an audited stage-gate model with predetermined milestones, verified analytical deliverables, and complete transfer packages.
Screening candidate botanicals for target secondary metabolites. Evaluating geographic origins, harvest windows, and plant anatomical segments.
Deliverable: Sourcing & Compound Target DossierSynthesizing reference standards and establishing validated HPLC, UHPLC, GC-MS, and HPTLC fingerprint methods to establish chemical identity.
Deliverable: Validated QC Assay & Method SOPsDefining physical extraction parameters: solvent-to-solid ratio, thermal duration, resin desorption curves, and crystallization conditions.
Deliverable: Critical Process Parameters (CPP) ReportExecuting cellular phenotypic in vitro tests and in vivo murine pharmacodynamic/toxicity protocols to verify therapeutic margins.
Deliverable: Preclinical Toxicology & Efficacy PackageConducting human trials (small-cohort dietary trials or GCP-monitored Phase I–IV clinical investigations) for regulatory substantiation.
Deliverable: Complete Clinical Study Report (CSR)Transferring validated processes to multi-ton extraction tanks and clean-room packaging for finished solid, liquid, or powder dosage forms.
Deliverable: Commercial Batches & Certificates of AnalysisOur contract research and CDMO supply solutions support leading pharmaceutical corporations, universities, and clinical healthcare systems.
Tongrentang Group
CR Sanjiu Medical
Sunflower Pharma
Livzon Pharma Group
Dihon Pharmaceutical
Golden Throat Holdings
Yangtze River Pharma
Beihai Gofar Chuanshan
Humanwell Healthcare
SCIMYTH Pharmaceutical
Shandong Hanfang Pharma
Luoxin Pharma Group
Zhongsheng Pharma
Hunan Brilliance & Abundance
Apeloa Pharmaceutical
Heng Chang Pharmaceutical
Baotou TCM
Kamp Medicine
Guangxi Santo Pharma
Hunan Kangshou Pharma
Jiangxi Juwang Pharma
Beijing Tcmages Pharma
Guizhou Ruihe Pharma
CR Jinchan Pharma
Kangmei Pharmaceutical
Hunan Tianjicaotang
Kingstone Unite Pharma
Shuguang Hospital (Shanghai TCM)
Hunan Affiliated TCM Hospital
1st Hosp. Hunan Univ. CM
2nd Xiangya Hosp. CSU
2nd Hosp. Hunan Univ. CM
Zhuzhou City TCM OrthopedicsKey considerations for sourcing directors, chief scientific officers, and product developers assessing custom botanical extraction and CRO contracts.
Select from our turnkey research study packages to resolve critical analytical, biological, and scale-up bottlenecks for your botanical product pipeline.
Full analytical development packages: HPTLC identification, HPLC quantification, GC-MS impurity detection, and validation dossiers.
Evaluating active ingredient concentrations across diverse agricultural microclimates, harvesting periods, and plant anatomy.
Advanced fractionation and chromatographic isolation of secondary plant metabolites aligned with specific bio-efficacy markers.
Cell culture screening, enzymatic assay panels, and cytotoxicity assessments delivering early proof-of-concept evidence.
Human clinical trials structured for health claim substantiation or pharmaceutical drug regulatory marketing approval.
Standard animal models assessing systemic efficacy, metabolic pathways, and sub-acute physiological safety profiles.
Industrial extraction parameter refinement, resin absorption kinetic studies, and spray drying optimization for commercial yields.
End-to-end commercial production of oral liquids, softgels, capsules, tablets, and powders backed by validated QC testing.
Share your project specifications (target active molecules, intended therapeutic claims, desired finished dosage form, and destination regulatory requirements). Our scientific leadership team will prepare a structured study protocol, analytical method validation framework, and scale-up roadmap.
